Cambridge Discovery Park
100 Acorn Park Drive, 6th Floor
About LifeMine Therapeutics
LifeMine is the first company to massively scale the genomic discovery of powerful new drug modalities from eukaryotic microbes. Our integrated, genomically-enabled drug discovery engine is poised to deliver a pipeline of medicines that will conquer previously unconquerable human diseases.
The company has succeeded in hacking an evolutionary code in biosynthetic genes, creating a springboard for rapid discovery of naturally inspired drugs that function in unexpected ways. These medicines transcend the standard playbook of drug design.
LifeMine grew out of visionary founder Gregory Verdine’s life passion to discover and commercialize new drug modalities. YEAR FOUNDED:
Founders: Gregory Verdine Ph.D., WeiQing Zhou M.B.A., Richard Klausner M.D. and Hingge Hsu M.D., M.B.A.
President, CEO and CSO: Gregory Verdine Ph.D.
COO: WeiQing Zhou M.B.A.
VP, Genomic Discovery: Brian Bowman, Ph.D.
7 articles with LifeMine Therapeutics
1/8/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
LifeMine Therapeutics Inc, a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced the appointment of William G. Kaelin Jr., M.D., to its board of directors. Dr. Kaelin is the Sidney Farber Professor in the Department of Medicine at the Dana-Farber Cancer Institute and at the Brigham and Women's Hospital at Harvar
Proceeds will enable advancement and acceleration of the Company’s transformative drug discovery programs derived from digital search of the fungal biosphere to discover and develop highly impactful precision medicines Significant recent scientific and operational progress includes acquisition of exquisitely biodiverse fungal strain collections amassed by Merck and Pfizer, among others, and the appointment of Nobel Laureate William G. Kaelin, Jr.,
LifeMine Therapeutics Powers Drug Discovery Team to Search the Biosphere for Nature's Evolved Solutions to Intractable Therapeutic Challenges
LifeMine Therapeutics today announced several key appointments to its drug discovery team to include, Iain McFadyen, Ph.D., as Chief Data Officer; Jared Cumming, Ph.D., as Senior Vice President and Head of Chemistry; and Dawn Thomspon, Ph.D., as Vice President and Head of Microbiology and Automation
Cambridge Discovery Park Building 400-500 Will be New Headquarters for FogPharma and LifeMine Therapeutics
The Bulfinch Companies, Inc. announced it has signed a 114,490 SF lease with FogPharma in building 400 at Cambridge Discovery Park.
Venture capital is hopping, attracted to some of the past several years' successes.